Audited Financial Results for the Quarter and year ended 31st March, 2026 along with Statutory Auditor''s Repot thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Link Pharma Chem Ltd reported a profit of Rs 7.69 Lakhs for FY26, a turnaround from a loss of Rs 102.73 Lakhs in FY25. Revenue from operations grew 7.9% to Rs 2,743.15 Lakhs from Rs 2,543.34 Lakhs. The company posted an operating profit of Rs 13.51 Lakhs before tax compared to a loss of Rs 140.25 Lakhs in the previous year. Total equity stands at Rs 1,278.92 Lakhs while total debt increased to Rs 730.41 Lakhs. The statutory auditors CNK & Associates LLP issued an unmodified opinion with no qualifications. The Board also approved re-appointment of key auditors and re-appointment of the Chairman and Managing Director (father-son duo).
The company has successfully returned to profitability after two consecutive years of losses, which is a positive signal for shareholders. However, revenue growth remains modest at under 8% and the company posted a loss in Q4, indicating uneven performance across quarters. Increased borrowings warrant monitoring.